Fiche centre
CHU de Nantes
Nantes — France
Essais liés10clinical trials
VilleNanteslocalisation
PaysFrancelocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05481879
Essais cliniques associés
10| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Atrial flutter ablation | Maladie coronarienne | Non applicable | NCT01521988 | PAF CRIOBLAF — Cryoballoon Pulmonary Venous Isolation in Patients Referred for Typical Atrial Flutter Ablation | COMPLETED |
| CLN-978 | Lupus | Phase 1 | NCT06613360 | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus | RECRUITING |
| DYNE-101 | Myopathies | Phase 1/2 | NCT05481879 | ACHIEVE — Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 | ACTIVE_NOT_RECRUITING |
| synovial biopsy | Myopathies | Non applicable | NCT07503821 | SYVIPRO — Synovial Tissue as a Biomarker in the Management of Pigmented Villonodular Synovitis | RECRUITING |
| low-calorie low-protein | Myopathies | Non applicable | NCT03573739 | NUTRIREA3 — Impact of Early Low-Calorie Low-Protein Versus Standard Feeding on Outcomes of Ventilated Adults With Shock | COMPLETED |
| Fludarabine, Busulfan, Thymoglobuline | Cancer | Phase 2 | NCT00841724 | ITT 08-01 — Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies | COMPLETED |
| Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated | Hypertension | Non applicable | NCT06059638 | BACKBEAT — BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | RECRUITING |
| INNOVAN — Multiparametric Ultrafast Ultrasound Biomarkers for Duchenne and Becker Muscular Dystrophies | Myopathies | À vérifier | NCT07378553 | INNOVAN — Multiparametric Ultrafast Ultrasound Biomarkers for Duchenne and Becker Muscular Dystrophies | RECRUITING |
| Sevasemten 10 mg | Myopathies | Phase 2 | NCT05291091 | Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON) | COMPLETED |
| Sevasemten | Myopathies | Phase 2 | NCT06066580 | MESA — Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy | ENROLLING_BY_INVITATION |